PRESS RELEASE

Frost & Sullivan Awards Diabetology Limited
Entrepreneurial Company of the Year Award 2011 in Diabetes Therapeutics

Award recognizes Diabetology’s superior growth strategy and implementation excellence, important technology innovation, and their effective leverage of core competencies - all of which Frost & Sullivan believes sets Diabetology apart in a highly competitive market.

Based on their recent analysis of the diabetes therapeutics market, Frost & Sullivan has honoured Diabetology Limited with the European Entrepreneurial Company of the Year Award 2011 in Diabetes Therapeutics.

Having considered the key challenges that need to be addressed for the growing global diabetic patient population, Frost & Sullivan benchmarked Diabetology’s performance across the following criteria against key competitors:
- Growth Strategy Excellence
- Growth Implementation Excellence
- Degree of Innovation with Products and Technologies
- Leadership in Customer Value
- Speed of Response to Market Needs

Frost & Sullivan recognized that Diabetology outperformed all key competitors across these criteria and Siddharth Saha, Director of Research Frost & Sullivan stated, “Diabetology Limited, through the effective leverage of its core competencies, has been able to transform itself from a research-based company to an established diabetes company. The company has also managed to build relationships and raise its profile through its active seeking of collaborations and out-licensing programs involving products such as Oral Insulin and Oral GLP-1. The highly skilled key personnel have concentrated on the careful and selective application of an innovative technology platform and it is this, combined with the quick success of the clinical studies and the commercial focus of the management of the company, that reflects the company’s true entrepreneurial spirit.”

Diabetology’s co-founder, Glen Travers, commented: “We are delighted to receive this prestigious award from Frost & Sullivan in recognition of the significant effort that our entire team has put in to address the everyday needs and improve the quality of life of the many millions of diabetes patients worldwide. Our work, which has resulted in the development of useful and relevant products such as Capsulin oral insulin, allows and encourages the more effective use of well-proven therapeutic products for diabetes and thereby has the potential to improve public health throughout the world.”

Roger New, CSO and co-founder, pointed out, “administering insulin via the oral route, as Diabetology is doing, delivers it directly to the liver, the major target organ for insulin. In addition, it reduces the amount reaching the bloodstream, where high levels can lead to undesirable side effects. Thus the advantage of Capsulin oral insulin can be not only convenience for the patient, but increased safety, and an improved efficacy profile, similar to that in healthy individuals.”

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth
interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

NOTES TO EDITORS

**About Diabetology Limited**

Diabetology is a specialty biopharmaceutical company employing a proprietary oral delivery system to administer known bioactives as well as novel compounds for the comprehensive management of diabetes.

Diabetology's lead project is Capsulin, an oral encapsulated formulation of recombinant human insulin for the treatment of patients with type 1 and type 2 diabetes. Diabetology intends to develop Capsulin both as a novel oral anti-diabetic agent for the treatment of patients with type 2 diabetes (Capsulin OAD) and as a replacement to injectable insulin for patients suffering from type 1 and type 2 diabetes (Capsulin IR).

The company's innovative drug delivery technology, Axcess™ Oral Drug Delivery System, significantly increases the absorption of peptides, proteins and other macromolecules across the intestinal wall when delivered orally without any chemical modification of the active compounds. It is based on a simple mixture of components consisting entirely of registered pharmacopoeial or GRAS excipients with a long history of pharmaceutical use. The absorption enhancing activities obtained from the formulation of these excipients is entirely novel and forms the basis of five international patent applications. Diabetology has licensed exclusive rights to Axcess™ for the formulation of oral therapies for diabetes.

**About Frost & Sullivan**

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.